CoChat

Different Effects of Epigenetic Modifiers on the Cytotoxicity Induced by 5-Fluorouracil, Irinotecan or Oxaliplatin in Colon Cancer Cells

Open access
Ikehata, Mika, Ogawa, Mao, Yamada, Yasuki, Tanaka, Shota, Ueda, Kumiko, Iwakawa, Seigo · 2014 · Biological and Pharmaceutical Bulletin

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

We investigated the effects of epigenetic modifiers such as DNA methyltransferase (DNMT) or histone deacetylase (HDAC) inhibitors on the cytotoxicity induced by 3 anticancer drugs (5-fluorouracil (5-FU), irinotecan (CPT-11) or its active form SN38, and oxaliplatin (L-OHP)) in human colorectal cancer (CRC) cells. Cytotoxicity in 4 CRC cell lines (HT29, SW480, SW48 and HCT116) was examined by colorimetric assay after drug treatment for 72 h. The effects of drug combinations were analyzed by an isobologram method. SW480 cells showed the lowest sensitivity to cytotoxicity induced by the anticancer drugs among the 4 CRC cell lines. In SW480 cells, DNMT inhibitors, such as decitabine (DAC), azacytidine and zebularine (Zeb), showed synergic effects on the cytotoxicity induced by anticancer drugs except for SN-38 plus Zeb, while HDAC inhibitors, trichostatin A, suberoylanilide hydroxamic acid and valproic acid, showed antagonistic effects. DAC showed the most potent synergic effects among the epigenetic modifiers studied. Thus, we examined whether the synergic effect of DAC is observed in other different CRC cell lines, HT29, SW48 and HCT116 cells. In all 4 CRC cell lines, the cytotoxicity of L-OHP was enhanced in a synergic manner by co-treatment with DAC. However, synergic effects of DAC with 5-FU or CPT-11 (SN-38) were not observed in 4 CRC cell lines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1248/bpb.b13-00574

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 45

Metadata

Authors
Ikehata, M., Ogawa, M., Yamada, Y., Tanaka, S., Ueda, K., & Iwakawa, S.
Affiliations
Kobe Pharmaceutical University (JP)
Venue
Biological and Pharmaceutical Bulletin
Published
2014
Volume
37
Issue
1
Pages
67-73
ISSN
  • 0918-6158 (ISSN-L)
  • 1347-5215
OpenAlex
W2054808842
Cited by
42
References
28
Citations by year
2025: 3 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 6 · 2017: 3 · 2016: 4 · 2015: 2
FWCI
0.90
Type
journal article
Language
en
Open access
Locations
  • Biological and Pharmaceutical Bulletin (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
epigenetic regulators, colorectal cancer, 5-fluorouracil, irinotecan, SN-38, oxaliplatin, hypomethylating agents, histone deacetylase inhibitors, decitabine, azacitidine, zebularine, trichostatin A, vorinostat, valproic acid, drug synergy, drug antagonism, cytotoxicity, combination therapy
MeSH terms
Irinotecan, Oxaliplatin, Decitabine, Antimetabolites, Antineoplastic, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Camptothecin, Colonic Neoplasms, DNA, Drug Synergism, Fluorouracil, Humans, Organoplatinum Compounds, DNA Modification Methylases, HT29 Cells, Epigenesis, Genetic, HCT116 Cells, Cell Line, Tumor, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.